The Annual Cardiovascular Review Every Man Over 40 Should Have.

The annual physical tells you whether you are alive and whether your numbers fall within population reference ranges. It does not tell you whether your cardiovascular trajectory is improving, stable, or worsening. That requires tracking specific measurements year over year against defined targets, using a consistent protocol so that comparisons across time mean something.

The Mechanism

Cardiovascular risk is not static. It accumulates over years through processes that are individually subtle and collectively consequential: LDL particle deposition into arterial walls, endothelial dysfunction from chronic blood pressure elevation, insulin resistance that progressively impairs vascular function, and autonomic imbalance that prevents adequate nighttime recovery. None of these processes produce symptoms while they are developing. They produce symptoms when they are far enough along to cause acute events.

The reason annual monitoring matters is not that a single reading tells you your risk. A single reading tells you your current value. What tells you your risk trajectory is the comparison of this year’s value to last year’s value, tracked against a defined target, repeated consistently enough to distinguish trend from noise.

A man who has measured his ApoB at 118 mg/dL for three consecutive years without change has a different risk picture than a man whose ApoB has moved from 118 to 104 to 91 over the same period. Both of them might appear healthy at any single measurement without context. The trajectory is the clinical information.

The same logic applies to blood pressure, metabolic markers, and functional measures like resting heart rate. None of these is informative as an isolated snapshot. They become informative when they have a direction and a comparison point. This is why the protocol for this review specifies not just which tests to run but how to compare them year over year and what specific numbers constitute meaningful movement.

For men specifically, the window for intervention on cardiovascular risk is widest in the forties and fifties. Atherosclerotic plaque that has been forming for years without clinical consequence is still in a range where pharmacological and lifestyle intervention can substantially reduce event risk. By the time a first event occurs, that window is substantially narrower. The rationale for starting this review by age 40, and continuing it annually, is that the decade before the highest-risk period is when preventive work has the most impact.

What the Evidence Shows

The clinical validation for individual biomarker targets comes from multiple large studies, and it is worth being specific about what the evidence supports and what it does not.

ApoB as the primary lipid target: The 2019 European Society of Cardiology guidelines and the accompanying European Atherosclerosis Society lipid guidelines formally endorsed ApoB over LDL-C as the preferred measure of atherogenic particle burden, citing data from multiple large studies including the AMORIS cohort (Wallberg-Jonsson and colleagues, involving over 100,000 participants) and the INTERHEART study. ApoB directly counts the number of atherogenic particles in circulation, where LDL-C estimates only the cholesterol content within those particles. Two people with the same LDL-C can have substantially different ApoB values and substantially different cardiovascular risk based on particle number differences. 5 / Solid

The ApoB target of below 90 mg/dL for primary prevention and below 70 mg/dL for those with established risk factors or existing cardiovascular disease comes from guideline consensus, with the lower thresholds supported by the FOURIER and ODYSSEY trials showing that lower ApoB levels achieved through PCSK9 inhibition produced further cardiovascular event reduction even in patients already on statin therapy at standard doses. 5 / Solid

Home blood pressure monitoring: Ambulatory and home blood pressure monitoring are more predictive of cardiovascular outcomes than clinic readings, according to a 2018 meta-analysis by Stergiou and colleagues published in Hypertension involving data from 12 cohort studies and more than 17,000 participants. Home monitoring eliminates the white-coat effect and captures the average that governs long-term vascular exposure. The specific protocol of seven consecutive mornings with two readings per morning, averaged, comes from the International Society of Hypertension 2020 guidelines. 4 / Promising

Fasting insulin as a metabolic marker: Standard clinical panels do not include fasting insulin, which means most men with early insulin resistance will not receive a flag on their routine labs until HbA1c rises above 5.7 percent. But fasting insulin elevation precedes HbA1c elevation by years in the natural history of metabolic syndrome. A 2002 analysis by Haffner and colleagues showed that cardiovascular risk begins rising with insulin resistance well before formal diabetes criteria are met. Fasting insulin above 10 uIU/mL in a non-diabetic individual warrants attention even when HbA1c is normal. The target for trajectory tracking is consistent downward movement in response to dietary and activity interventions, with the goal of sustaining a value below 8 to 10 uIU/mL. 4 / Promising

Resting heart rate: Multiple large epidemiological studies support resting heart rate as an independent cardiovascular risk predictor. A 2010 analysis by Fox and colleagues in Lancet, drawing from the CLARIFY registry, found that each 10-beat increase in resting heart rate was associated with a 13 percent increase in all-cause mortality and an 18 percent increase in cardiovascular mortality, after adjusting for traditional risk factors. The target of below 65 beats per minute for tracking purposes aligns with the range in which risk relationships begin to flatten in population data. 4 / Promising

Coronary artery calcium scoring: The CAC score is the most direct non-invasive measure of subclinical atherosclerosis, and its predictive value for cardiovascular events is well established. The MESA study, involving over 6,000 participants across multiple ethnic groups, found that CAC score substantially reclassified intermediate-risk individuals up or down on 10-year risk, outperforming traditional risk factors and several blood biomarkers for event prediction at the individual level. The reassessment intervals, five to seven years for CAC of zero and three to five years for CAC of 1 to 100, come from MESA follow-up analyses showing that event rates in the CAC zero group remain low enough that annual rescoring adds no clinical information. 4 / Promising

Three Secondary Measurements Worth Tracking

Beyond the four primary biomarkers, several secondary measurements add meaningful information when tracked consistently over years rather than reviewed once and set aside.

Waist circumference. Measured at the navel, not the belt line. Target: below 40 inches for men. Waist circumference is a proxy for visceral adipose tissue, which is metabolically distinct from subcutaneous fat and carries independent cardiovascular risk. Visceral fat produces inflammatory cytokines, contributes to insulin resistance, and correlates more closely with cardiovascular events than body mass index in most epidemiological studies. A man whose BMI is in the normal range but whose waist circumference is 44 inches has a different cardiovascular risk profile than his weight suggests. Track it quarterly and note the annual change.

hsCRP. High-sensitivity C-reactive protein is a marker of systemic inflammation. Its role in cardiovascular risk prediction was established by the JUPITER trial, in which Ridker and colleagues at Brigham and Women’s Hospital demonstrated that statin therapy reduced cardiovascular events significantly in patients with elevated hsCRP and normal LDL-C. The target for hsCRP is below 2 mg/L. Persistent elevation above this threshold after lifestyle optimization is worth investigating: the most common causes are untreated obstructive sleep apnea, excess visceral adiposity, insulin resistance, and, less commonly, chronic inflammatory or autoimmune conditions. Do not add statin therapy on the basis of hsCRP elevation alone without addressing the underlying drivers first.

HRV trend from wearable data. Heart rate variability as a single reading is nearly meaningless. A 90-day average from the same device under comparable conditions is informative. The direction of that trend over 6 to 12 months tells you whether your autonomic balance is improving or declining. A falling HRV trend in a man who reports worsening sleep, increasing stress load, and no change in aerobic activity represents an early warning of autonomic deterioration before any clinical measurement flags. Most modern consumer wearables produce HRV estimates that are not clinically calibrated but are consistent enough within the same device to track trend. Note the 90-day average at each annual review and compare it to the prior year.

Lp(a), measured once. Lipoprotein(a) is a genetically determined lipoprotein with atherogenic and prothrombotic properties. Approximately 20 percent of the population carries Lp(a) above 50 mg/dL, which independently elevates cardiovascular risk and does not respond to statins or standard dietary modification. The 2022 European Society of Cardiology guidelines recommend measuring Lp(a) at least once in every adult to identify this genetically elevated risk. It is not an annual test because it does not change: if your Lp(a) is 180 nmol/L at age 40, it will be 180 nmol/L at age 60. But not knowing it means not knowing a significant portion of your actual risk picture. If your Lp(a) is elevated, your treatment targets for ApoB and blood pressure should be more aggressive, and your cardiologist needs this data to calibrate those targets correctly. 4 / Promising

The Resting ECG at Annual Review: Incidental Findings With Clinical Weight

A resting 12-lead electrocardiogram takes less than five minutes, costs less than most blood panels, and generates information that no biomarker replaces. Yet in many annual cardiovascular reviews for men without known cardiac disease, it is either omitted or ordered only when symptoms are reported. The 2018 USPSTF statement recommends against routine ECG screening in low-risk asymptomatic adults, based on evidence that false-positive findings in that population generate unnecessary downstream testing without mortality benefit. The key phrase is low-risk: that recommendation does not apply to the intermediate and higher-risk population that makes up most of a preventive cardiology practice.

What a resting ECG can reveal in an asymptomatic man carries prognostic weight that the biomarker panel cannot provide. Left ventricular hypertrophy on ECG is independently associated with increased cardiovascular risk beyond the blood pressure reading that prompted it. Levy and colleagues, analyzing serial Framingham data, demonstrated that ECG evidence of LVH regression over time was associated with significant reductions in cardiovascular events — the inverse implication being that persistent or worsening ECG-LVH signals ongoing pressure load on the myocardium even when office blood pressure appears controlled. A man whose resting ECG shows LVH but whose office readings are within range warrants ambulatory blood pressure monitoring to exclude masked hypertension before the ECG finding is attributed to prior load and documented as stable.

New left bundle branch block in a man without prior cardiac evaluation warrants investigation rather than monitoring. Grady and colleagues, analyzing outcomes data published in the Journal of the American College of Cardiology, found that new left bundle branch block in individuals without known structural heart disease was associated with a five- to tenfold higher risk of subsequent coronary events compared to matched controls without conduction abnormalities. An asymptomatic man with newly identified left bundle branch block on his annual ECG is not a case where watchful waiting is the appropriate initial response.

QTc prolongation above 450 milliseconds in men is independently associated with increased cardiovascular mortality. In a man taking medications with QT-prolonging potential — certain antibiotics, antihistamines, antidepressants, or antifungals — a baseline ECG provides the reference point that makes future QTc changes interpretable. Without a baseline, a reading of 470 milliseconds has no context for determining whether it represents a new development or a longstanding finding. The annual ECG is a longitudinal document: comparing this year’s tracing to last year’s is where the clinical signal lives, and serial comparison rather than single-point interpretation is what that tracing is for.

What to Do This Week

1. Build a tracking log before your next physician visit. Create a simple document with columns for date, ApoB, home blood pressure seven-morning average, fasting insulin, resting heart rate, waist circumference, and HbA1c. Enter whatever values you have now, even if most cells are blank. The blank cells are the agenda for your next lab visit. Bring this document to every annual review.

2. Schedule a visit framed explicitly as a cardiovascular risk review rather than a general physical. Tell the scheduling team that you want to discuss cardiovascular biomarker targets and get the specific tests ordered. Most general annual physicals do not automatically include ApoB, fasting insulin, or Lp(a). You need to request them.

3. If you have never had your Lp(a) measured, add it to this year’s labs. Lp(a) is a genetically determined lipoprotein that is not reduced by statins or standard dietary interventions and is an independent cardiovascular risk factor. It is measured once, not annually, because it does not change meaningfully over time. But without measuring it, you do not know whether you carry that additional risk.

4. If you are over 40 and have never had a coronary artery calcium score, discuss whether it is appropriate for your risk profile. The MESA study data show that CAC reclassifies intermediate-risk individuals more accurately than any blood biomarker panel. A CAC score of zero in a 48-year-old with borderline ApoB may support a conservative approach to statin therapy. A CAC score of 200 in the same individual supports a more aggressive one. The conversation with your cardiologist requires the data point to be meaningful.

5. Set a calendar reminder for this review annually, not when something feels wrong but as a fixed event. The value of annual tracking is that it requires no justification beyond the passage of one year. The trajectory only becomes visible if the measurements are made consistently at regular intervals.

The trend is the information. A single reading tells you where you are. A series of readings tells you where you are going. For the cardiovascular system, those two things are not the same, and only one of them can drive preventive decisions.